TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31064641

Group type: EXPERIMENTAL
Intervention: EX-PLISSIT model counselling (two 1-hour sessions each week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 80
Study: 27208318

Group type: EXPERIMENTAL
Intervention: Light-intensity walking (LW)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simple resistance activities (SRA)
Number of subjects: 24
Study: 24946982

Group type: EXPERIMENTAL
Intervention: Ceram X/Prime&Bond NT
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Tetric Ceram/Optibond Solo Plus
Number of subjects: 456
Study: 22421317

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, church-based, multi-component, motivational enhancement intervention including self-help materials, motivational interviewing calls, newsletters, health promotion activities, and peer support workshops.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (churches not receiving the intervention).
Number of subjects: 400
Study: 19084115

Group type: EXPERIMENTAL
Intervention: Ozone delivery system (HealOzone; KaVo, Biberach, Germany)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study: 17449592

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15 mg retinol equivalent)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 1077
Study: 15858816

Group type: EXPERIMENTAL
Intervention: Consolidation workshops (6 workshops, 3 hours each)
Number of subjects: 62
Study: 12789993

Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel (18% carbamide peroxide)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Commercially available whitening dentifrice
Number of subjects: 97
Study: 9607830

Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate (750 mg and 1000 mg three times daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate (open-label extension with nucleoside inhibitors of reverse transcriptase)
Number of subjects: 65
Study: 7883843

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2136198

Group type: EXPERIMENTAL
Intervention: Intraoperative air testing (test group)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No intraoperative air testing (no test group)
Number of subjects: 143
Study: 355182

Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 40
Study: 30541378

Group type: EXPERIMENTAL
Intervention: Mums Step It Up (MSIU) Facebook app (n=41)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pedometer only (n=39)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 120
Study: 26044933

Group type: EXPERIMENTAL
Intervention: Plasmakinetic vapor enucleation of the prostate (PVEP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Plasmakinetic resection of the prostate (PKRP)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both PVEP and PKRP
Number of subjects: 112
Study: 23547971

Group type: EXPERIMENTAL
Intervention: Standard time-based Green Prescription
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Modified pedometer-based Green Prescription
Number of subjects: 225
Study: 22242350

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) at 3.5 W
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU) at 4.0 W (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU) at 4.5 W (Group C)
Number of subjects: 60
Study: 19699334

Group type: EXPERIMENTAL
Intervention: Transradial PCI with maximal antiplatelet therapy (aspirin, clopidogrel, and abciximab)
Number of subjects: 1348
Study: 16449108

Group type: EXPERIMENTAL
Intervention: Ethanolic St. John's wort extract and isopropanolic black cohosh extract
Number of subjects: 301

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 301
Study: 15566422

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg daily for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11553137

Group type: EXPERIMENTAL
Intervention: Excipial Protect (containing aluminium chlorohydrate 5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study: 8985259

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Normolipidemic subjects
Number of subjects: 86
Study: 7691342

Group type: EXPERIMENTAL
Intervention: Incidental teaching procedures; utilized in a multiple-baseline fashion across three sequential environments.
Number of subjects: 0
Study: 3084952

Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (1.4-2.0 g/kg body weight, two doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (two doses in the morning)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (2-3 g/kg body weight every 6 hours)
Number of subjects: 12
Study: 29544870

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Canakinumab (all doses)
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 10061
Study: 27353607

Group type: EXPERIMENTAL
Intervention: Updated patient information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline model of overall mortality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Updated model
Number of subjects: 0
Study: 25522731

Group type: EXPERIMENTAL
Intervention: Web-based training plus telephone consultation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based training only
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study: 22301107

Group type: EXPERIMENTAL
Intervention: Drug-releasing implants
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-drug-releasing implants
Number of subjects: 105
Study: 20044472

Group type: EXPERIMENTAL
Intervention: LOW‐CHO
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LOW‐EN
Number of subjects: 9

Group type: COMPARATOR
Intervention: BAL
Number of subjects: 9

Group type: COMPARATOR
Intervention: CON
Number of subjects: 9
Study: 18842753

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for depression
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1233
Study: 16364862

Group type: EXPERIMENTAL
Intervention: C2 monitoring of cyclosporine levels
Number of subjects: 125

Group type: COMPARATOR
Intervention: C0 monitoring of cyclosporine levels
Number of subjects: 125
Study: 11805583

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg per day)
Number of subjects: 21796

Group type: COMPARATOR
Intervention: Dietary vitamins C and E and beta‐carotene
Number of subjects: 21796

Group type: COMPARATOR
Intervention: Long‐term vitamin E and beta‐carotene supplementation
Number of subjects: 21796
Study: 10409572

Group type: EXPERIMENTAL
Intervention: Low dose dexamethasone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7589024

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Zolpidem (5, 10, or 15 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg or 0.25 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2260872

Group type: EXPERIMENTAL
Intervention: High-dose dl-Leucovorin (500 mg/m2) and 5-FU (600 mg/m2)
Number of subjects: 61
Study: 6768078

Group type: EXPERIMENTAL
Intervention: Heroin self-administration with naltrexone placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heroin self-administration with buprenorphine placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heroin self-administration
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline and heroin conditions
Number of subjects: 11
Study: 6669628

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alcohol (0.5 g/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zopiclone plus Alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunitrazepam plus Alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30102686

Group type: EXPERIMENTAL
Intervention: Active Recovery Group (ARG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive Recovery Group (PRG)
Number of subjects: 14
Study: 29282360

Group type: EXPERIMENTAL
Intervention: High total serum cholesterol
Number of subjects: 4974

Group type: EXPERIMENTAL
Intervention: High HDL
Number of subjects: 4974

Group type: EXPERIMENTAL
Intervention: LDL levels
Number of subjects: 4974
Study: 26815931

Group type: EXPERIMENTAL
Intervention: Decentralized Optical Coherence Tomography (OCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Centralized photography suite (Control)
Number of subjects: 0
Study: 24650448

Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/d
Number of subjects: 780
Study: 22817651

Group type: COMPARATOR
Intervention: Tranexamic acid (Group B)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Clamping of drain with placebo (Group D)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clamping of drain with tranexamic acid (Group D)
Number of subjects: 240
Study: 19815376

Group type: EXPERIMENTAL
Intervention: Focused attention/mindfulness induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfocused attention induction
Number of subjects: 0
Study: 17961428

Group type: EXPERIMENTAL
Intervention: Brugada syndrome patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Brugada syndrome patients without cardiac events
Number of subjects: 23
Study: 16140230

Group type: EXPERIMENTAL
Intervention: Supervised home exercise programme (twice-weekly for 6 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 31
Study: 12096962

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost and 0.5% timolol combination therapy
Number of subjects: 418

Group type: COMPARATOR
Intervention: 0.005% latanoprost monotherapy
Number of subjects: 418

Group type: COMPARATOR
Intervention: 0.5% timolol monotherapy
Number of subjects: 418
Study: 10445599

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 250 microg, two puffs b.i.d. for 6 weeks
Number of subjects: 40
Study: 7798505

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (25 mg of aspirin and 200 mg of dipyridamole twice daily)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 215
Study: 2346545

Group type: EXPERIMENTAL
Intervention: Fenticonazole 2% cream
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenticonazole spray
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Miconazole 2% cream
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Econazole 1% spray
Number of subjects: 12
Study: 393378

Group type: EXPERIMENTAL
Intervention: PACe (Cis-dichlorodiammineplatinum(II) 80 mg/m2 iv Day 1, Adriamycin 40 mg/m2 iv Day 1, cyclophosphamide 200 mg/m2 orally Days 2-5)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) (CDDP) alone (80 mg/m2 Day 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cis-dichlorodiammineplatinum(II) (CDDP)
Number of subjects: 28
Study: 28570491

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CT (Continuous Training)
Number of subjects: 20
Study: 29400014

Group type: EXPERIMENTAL
Intervention: Initial treatment with oral MPA (400-600 mg/day)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Repeated treatment with oral MPA (400-600 mg/day)
Number of subjects: 244
Study: 27998860

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral blockade (group A, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia with tracheal intubation (group B, n=60)
Number of subjects: 120
Study: 24390871

Group type: EXPERIMENTAL
Intervention: Structured heart failure education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single lecture on the disease (Control)
Number of subjects: 0
Study: 23033884

Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: nothing (control)
Number of subjects: 78
Study: 19667111

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adiponectin neutralizing antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipocyte conditioned medium
Number of subjects: 0
Study: 17454036

Group type: EXPERIMENTAL
Intervention: Controlled release (CR) tablets of naproxen sodium
Number of subjects: 6

Group type: COMPARATOR
Intervention: Marketed immediate release tablets of naproxen sodium
Number of subjects: 6
Study: 15154604

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 20
Study: 11739070

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9431857

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (one or a combination of two first-line antihypertensive drugs) for 6 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 54
Study: 8099804

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (50 mg vitamin C)
Number of subjects: 12
Study: 3687354

Group type: EXPERIMENTAL
Intervention: Detailed information for at least 20 min
Number of subjects: 81

Group type: COMPARATOR
Intervention: Routine information for about 5 min
Number of subjects: 81
Study: 30361237

Group type: EXPERIMENTAL
Intervention: Probenecid (PROB) 1000 mg orally
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Probenecid (PROB) 1000 mg orally with Furosemide (FSM) 40 mg orally
Number of subjects: 14

Group type: COMPARATOR
Intervention: Furosemide (FSM) 40 mg orally
Number of subjects: 14
Study: 28814399

Group type: COMPARATOR
Intervention: 0 g soybean oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 g soybean oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 g soybean oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8 g soybean oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 32 g soybean oil
Number of subjects: 12
Study: 26507916

Group type: EXPERIMENTAL
Intervention: Panda (smartphone version of FPS-R)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Panda (smartphone version of CAS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Original FPS-R
Number of subjects: 128

Group type: COMPARATOR
Intervention: Original CAS
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Preference for assessment tool
Number of subjects: 128
Study: 23899930

Group type: EXPERIMENTAL
Intervention: Quality indicators for medications (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, aldosterone antagonists, hydralazine/nitrates, statin therapy, and warfarin)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quality indicators for use (or planned use) of implantable intracardiac devices
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quality indicators for blood pressure control (<140/90 mm Hg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regional variations in quality indicators
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Temporal variation of quality indicators
Number of subjects: 32
Study: 20647942

Group type: EXPERIMENTAL
Intervention: Whole-body vibration squatting (WBVS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study: 19423515

Group type: EXPERIMENTAL
Intervention: Amplicor at 0.2 cutoff
Number of subjects: 3277

Group type: EXPERIMENTAL
Intervention: Amplicor at 1.5 cutoff
Number of subjects: 3277

Group type: COMPARATOR
Intervention: hc2
Number of subjects: 3277

Group type: EXPERIMENTAL
Intervention: Amplicor
Number of subjects: 3277
Study: 16753014

Group type: EXPERIMENTAL
Intervention: 5 microg vitamin D3 supplementation
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 10 microg vitamin D3 supplementation
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 212
Study: 15546233

Group type: EXPERIMENTAL
Intervention: Repressor group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-anxious group
Number of subjects: 91

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 91
Study: 11744466

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Alfuzosin 15 mg OD
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 8626364

Group type: EXPERIMENTAL
Intervention: Nefazodone (100-600 mg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nefazodone and Sertraline
Number of subjects: 160
Study: 1420736

Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 18

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 6607151

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0
Study: 31288630

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Allulose
Number of subjects: 20
Study: 31563804

Group type: EXPERIMENTAL
Intervention: Text message intervention providing personalized normative feedback
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 183
Study: 29878382

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks
Number of subjects: 2888

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks
Number of subjects: 2888

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2888
Study: 27931214

Group type: EXPERIMENTAL
Intervention: Volunteer support intervention (tailored face-to-face support, 2-3 hours per week)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 196
Study: 24948798

Group type: EXPERIMENTAL
Intervention: Prolonged training at threshold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double training paradigm
Number of subjects: 0
Study: 22508366

Group type: EXPERIMENTAL
Intervention: Prolonged fasting with food-related visual and odorous stimuli
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prolonged fasting without food-related visual and odorous stimuli
Number of subjects: 12
Study: 20634300

Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone pulse for 3 days in months 1, 3, and 5, oral prednisone 0.5 mg/kg every other day, azathioprine 1.5 mg/kg per day for 6 months)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Corticosteroids alone (same schedule as group 1)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Corticosteroids (with azathioprine)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 207
Study: 18085335

Group type: EXPERIMENTAL
Intervention: Group 2 (2001-2005)
Number of subjects: 42
Study: 15580441

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 47
Study: 11876694

Group type: EXPERIMENTAL
Intervention: Foam enema (2 g mesalazine per day, Claversal Foam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid enema (4 g mesalazine per day, Salofalk enema)
Number of subjects: 0
Study: 10030248

Group type: EXPERIMENTAL
Intervention: Adjunctive chemotherapy (neoadjuvant cisplatin 100 mg/m2 D1 and 5-fluorouracil 1 gm/m2 D1-D3, followed by four courses of the same after radiotherapy)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Radical radiotherapy alone (60-62.5 Gy nasopharyngeal dose)
Number of subjects: 618
Study: 7741286

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2.5 micrograms/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (0.07 mg/kg)
Number of subjects: 40
Study: 1416418

Group type: EXPERIMENTAL
Intervention: ANP infusion at 10.0 pmol/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP infusion at 1.25 pmol/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP infusion at 3.0 pmol/kg/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study: 3933317

Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin (GTN) 3 mg administered 3 times daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) 30 mg administered 4 times daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30117077

Group type: EXPERIMENTAL
Intervention: School-based intervention including classroom-based education sessions, take home assignments, and parenting workshops.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 0
Study: 28940681

Group type: EXPERIMENTAL
Intervention: Oral health education for caregivers and provision of ultrasonic cleaning devices
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group with continued normal care
Number of subjects: 269
Study: 25293676

Group type: EXPERIMENTAL
Intervention: New professional league players
Number of subjects: 408

Group type: COMPARATOR
Intervention: Amateur level players (control)
Number of subjects: 408